Barrow Hanley Mewhinney & Strauss LLC boosted its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 42.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,082,636 shares of the healthcare product maker's stock after buying an additional 1,511,461 shares during the quarter. Abbott Laboratories makes up approximately 1.6% of Barrow Hanley Mewhinney & Strauss LLC's holdings, making the stock its 15th largest holding. Barrow Hanley Mewhinney & Strauss LLC owned about 0.29% of Abbott Laboratories worth $502,317,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of ABT. BlackRock Inc. grew its stake in Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares in the last quarter. State Street Corp boosted its holdings in shares of Abbott Laboratories by 0.6% during the third quarter. State Street Corp now owns 81,431,110 shares of the healthcare product maker's stock worth $8,047,837,000 after acquiring an additional 504,876 shares during the period. Bank of America Corp DE bought a new position in Abbott Laboratories during the 2nd quarter worth $1,603,607,000. Deutsche Bank AG boosted its holdings in Abbott Laboratories by 18.6% in the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker's stock valued at $1,515,963,000 after purchasing an additional 2,614,965 shares during the period. Finally, Legal & General Group Plc acquired a new stake in Abbott Laboratories during the second quarter worth approximately $1,082,524,000. Institutional investors own 75.18% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on ABT shares. UBS Group reduced their target price on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a report on Tuesday, July 28th. Royal Bank Of Canada reduced their price objective on shares of Abbott Laboratories from $130.00 to $125.00 and set an "outperform" rating on the stock in a research note on Thursday, October 22nd. Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $112.00 to $119.00 and gave the company an "overweight" rating in a research report on Thursday, October 22nd. TD Cowen decreased their price target on shares of Abbott Laboratories from $135.00 to $118.00 and set a "buy" rating for the company in a research note on Thursday, October 22nd. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Abbott Laboratories from $120.00 to $118.00 and set an "overweight" rating on the stock in a report on Thursday, October 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $119.04.
Check Out Our Latest Stock Report on ABT
Abbott Laboratories Price Performance
Shares of Abbott Laboratories stock opened at $102.96 on Friday. The business's 50-day moving average price is $103.91 and its 200-day moving average price is $101.66. The firm has a market capitalization of $178.32 billion, a PE ratio of 19.97, a price-to-earnings-growth ratio of 1.88 and a beta of 0.54. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $129.85. The company has a current ratio of 1.45, a quick ratio of 1.00 and a debt-to-equity ratio of 0.57.
Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts' consensus estimates of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 18.04%. The firm had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. During the same period in the previous year, the business posted $1.30 EPS. The business's quarterly revenue was up 14.5% on a year-over-year basis. Sell-side analysts forecast that Abbott Laboratories will post 5.52 EPS for the current fiscal year.
Abbott Laboratories Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Monday, November 16th. Shareholders of record on Thursday, October 15th were given a $0.63 dividend. The ex-dividend date was Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories's payout ratio is presently 94.03%.
Insider Buying and Selling
In other Abbott Laboratories news, EVP Mary Moreland sold 3,500 shares of the company's stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $116.00, for a total value of $406,000.00. Following the completion of the transaction, the executive vice president directly owned 100,791 shares in the company, valued at approximately $11,691,756. This represents a 3.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.46% of the stock is owned by insiders.
Recent Abbott Laboratories Headlines
Investors following ABT have been watching these headlines:
- Positive Sentiment: Leerink Partners upgraded Abbott from “market perform” to “outperform” and set a $124 price target, citing a more favorable outlook for the company. The higher rating is a potential bullish catalyst. Article
- Positive Sentiment: Abbott initiated the VOYAGER CE trial of its investigational Encantor software-guided TAVI system for severe aortic stenosis. The technology is designed to improve valve deployment; successful development could strengthen Abbott’s cardiovascular device pipeline, though clinical and regulatory outcomes remain uncertain. Article
- Neutral Sentiment: Articles noting that ABT is up 1.3% since its last earnings report revisit the results and look to earnings estimates for clues, but provide no specific new estimate revisions or fresh financial results. Article
Abbott Laboratories Profile
(
Free Report)
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott's offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Abbott Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.
While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.